Skip to main content
      NEW biomarkers in #MAS
      1️⃣ IL-18 (available at some 🏥)⭐️
      2️⃣ S100A12
      3️⃣ CXCL9/10

      🚨When suspectin

      Artem Minalyan, MD, DABOM AMinalyan

      3 months 2 weeks ago
      NEW biomarkers in #MAS 1️⃣ IL-18 (available at some 🏥)⭐️ 2️⃣ S100A12 3️⃣ CXCL9/10 🚨When suspecting #MAS, don’t ignore the possibility of a monogenic disorder! 🎙️ Dr. Sophie Georgin-Lavialle 🇫🇷 #macrophage #EULAR2024 #genetics #rheumx https://t.co/Uot3JjrWs8
      DMOADs in #osteoarthritis at #EULAR2024: 1) Tonia Vincent: StepUp OA endotype SF proteomics —> endothelial to mesen

      Tuhina Neogi, MD, PhD Tuhina_Neogi

      3 months 2 weeks ago
      DMOADs in #osteoarthritis at #EULAR2024: 1) Tonia Vincent: StepUp OA endotype SF proteomics —> endothelial to mesenchymal transition proteins. 2) Phil Conaghan: proregenerative (& degeneration slowing) therapies in pipeline. 3) @Larhumato: novel RCT designs & structure outcomes
      POS0277: proof of concept: Prophlx with canakinumab x 1 dose rather than steroids/colch/NSAIDS when starting pegloticase

      TheDaoIndex KDAO2011

      3 months 2 weeks ago
      POS0277: proof of concept: Prophlx with canakinumab x 1 dose rather than steroids/colch/NSAIDS when starting pegloticase with MTX in pts with active, refractory gout: 11 pts: #gout flares 0 (compared 54% in MIRROR-C), infusion rxn 0, no safety signal @rheumnow https://t.co/4qFnQTOuq0
      Recommendation for management of fatigue in people with rheumatic disease.

      Considering fatigue as a surrogate for infl

      Nouf Al hemmadi NoufAhmedAlham2

      3 months 2 weeks ago
      Recommendation for management of fatigue in people with rheumatic disease. Considering fatigue as a surrogate for inflammation and changing medication accordingly is part of it. I will also add yearly blood work including: 1- VitD 2-HBA1c and LDl 3-TsH. https://t.co/3QvPqMxZSN
      Enjoyed the #PolymyalgiaRheumatica session at #EULAR2024? Make sure to download our first atlas imaging article, where @

      Rheumatology & Rheumatology Advances in Practice RheumJnl

      3 months 2 weeks ago
      Enjoyed the #PolymyalgiaRheumatica session at #EULAR2024? Make sure to download our first atlas imaging article, where @drceowen, @drdavidliew et al. characterise PMR using whole-body PET/CT 👀 ➡️ https://t.co/tbu0DgAFIS https://t.co/W06YbYyjRx
      Mapping the knee #osteoarthritis joint-nerve interactome — presented by @AM_Malf at #EULAR2024. Anatomical and molecul

      Tuhina Neogi, MD, PhD Tuhina_Neogi

      3 months 2 weeks ago
      Mapping the knee #osteoarthritis joint-nerve interactome — presented by @AM_Malf at #EULAR2024. Anatomical and molecular neuroplasticity occurs during OA onset + progression in the joint and DRG. Cool imaging of nerves and their activity with lightsheet microscopy in mice https://t.co/cre6LEVhle
      Potential efficacy of JAK inhibitors in VEXAS syndrome

      #EULAR2024
      NZ https://t.co/HziLUgo1gA

      Annals of the Rheumatic Diseases ARD_BMJ

      3 months 2 weeks ago
      Potential efficacy of JAK inhibitors in VEXAS syndrome #EULAR2024 NZ https://t.co/HziLUgo1gA
      EULAR treats its attendees to a wonderful lunch each day – Schnitzel, gnocchi, goulash at lunch after muffins and coffee in the morning. It's no wonder the meeting has been a lively one, well attended with a wealth of stimulating ideas, research and discussion. Here are a few of my favorite abstracts and presentations from today, day 3 in Vienna.
      500+ pts AxSPA
      No difference in drug discontinuation between IL-17i, TNFi, IL23i over time
      Adjusted for CRP, co-medicati

      Aurelie Najm AurelieRheumo

      3 months 2 weeks ago
      500+ pts AxSPA No difference in drug discontinuation between IL-17i, TNFi, IL23i over time Adjusted for CRP, co-medication w/ MTX + classic covariates IL-17i and IL-23i had experienced a higher number bDMARD failures #EULAR2024 POS0259 @RheumNow https://t.co/F3B6uXyAca
      Cohort from Netherlands 400+ PsA pts IR first bioDMARD
      300+ switched TNFi->IL-17i, 99 cycled TNFi->TNFi
      3year rete

      Aurelie Najm AurelieRheumo

      3 months 2 weeks ago
      Cohort from Netherlands 400+ PsA pts IR first bioDMARD 300+ switched TNFi->IL-17i, 99 cycled TNFi->TNFi 3year retention rates 12 mo 75% cyclers 80% swappers 24mo 60% cyclers 56% swappers No difference in treatment failure or DAS28 CRP #EULAR2024 @RheumNow POS0278 https://t.co/J8ONjVAFqG
      What is the meaning of mechanical stress-induced sacroiliac BMO MRI after childbirth in healthy women?

      5yrs follow up M

      Aurelie Najm AurelieRheumo

      3 months 2 weeks ago
      What is the meaning of mechanical stress-induced sacroiliac BMO MRI after childbirth in healthy women? 5yrs follow up MRI study shows: -decrease in BMO -1/3 BMO @ 5-year follow-up -15% ASAS definition of sacroiliitis -No correlation w/ symptoms @RheumNow #EULAR24 OP0222
      Understudied neurological involvement 🧠 in RA
      in pts > 65 vs. matched HC
      -larger lateral cerebral ventricles
      -brai

      Aurelie Najm AurelieRheumo

      3 months 2 weeks ago
      Understudied neurological involvement 🧠 in RA in pts > 65 vs. matched HC -larger lateral cerebral ventricles -brain atrophy -shrinkage of thalamus + frontal cortical regions -association w/ clinical depression @RheumNow POS0148 #EULAR2024 https://t.co/2mV4qGyBtW